================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2005
OR
[ ] TRANSITION REPORT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
FOR THE TRANSITION PERIOD FROM _______________ TO _______________
COMMISSION FILE NUMBER 0-24050
NORTHFIELD LABORATORIES INC.
(Exact name of registrant as specified in its charter)
DELAWARE 36-3378733
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
1560 SHERMAN AVENUE, SUITE 1000, EVANSTON, ILLINOIS 60201-4800
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (847) 864-3500
INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS
REQUIRED TO BE FILED BY SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE
REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH
FILING REQUIREMENTS FOR THE PAST 90 DAYS.
YES [X] NO [ ]
INDICATE BY CHECK MARK WHETHER THE REGISTRANT IS AN ACCELERATED FILER (AS
DEFINED IN RULE 12b-2 OF THE EXCHANGE ACT).
YES [X] NO [ ]
AS OF FEBRUARY 28, 2005, REGISTRANT HAD 26,745,239 SHARES OF COMMON STOCK
OUTSTANDING
================================================================================
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION
This Quarterly Report contains forward-looking statements concerning, among
other things, our prospects, clinical and regulatory developments affecting our
potential product and our business strategies. These forward-looking statements
are identified by the use of such terms as "intends," "expects," "plans,"
"estimates," "anticipates," "forecasts," "should," "believes" and similar terms.
These forward-looking statements involve risks and uncertainties. Actual results
may differ materially from those predicted by the forward-looking statements
because of various factors and possible events, including those discussed under
"Risk Factors" in our Annual Report on Form 10-K filed with the Securities and
Exchange Commission. Because these forward-looking statements involve risks and
uncertainties, actual results may differ significantly from those predicted in
these forward-looking statements. You should not place undue weight on these
statements. These statements speak only as of the date of this document or, in
the case of any document incorporated by reference, the date of that document.
All subsequent written and oral forward-looking statements attributable to
Northfield or any person acting on our behalf are qualified by the cautionary
statements in this section and in our Annual Report. We will have no obligation
to revise these forward-looking statements.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
Northfield Laboratories Inc.:
We have reviewed the balance sheet of Northfield Laboratories Inc. (a company in
the development stage) as of February 28, 2005, and the related statements of
operations for the three-month periods ended February 28, 2005 and February 29,
2004, and the statements of operations and cash flows for the nine-month periods
ended February 28, 2005 and February 29, 2004. We have also reviewed the
statements of shareholders' equity (deficit) for the nine-month period ended
February 28, 2005. These financial statements are the responsibility of the
Company's management.
We conducted our review in accordance with standards of the Public Company
Accounting Oversight Board (United States). A review of interim financial
information consists principally of applying analytical procedures to financial
data and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with the standards of the Public Company Accounting Oversight Board (United
States), the objective of which is the expression of an opinion regarding the
financial statements taken as a whole. Accordingly, we do not express such an
opinion.
Based on our review, we are not aware of any material modifications that should
be made to the financial statements referred to above for them to be in
conformity with accounting principles generally accepted in the United States of
America.
We have previously audited, in accordance with standards of the Public Company
Accounting Oversight Board (United States), the balance sheet of Northfield
Laboratories Inc. as of May 31, 2004, and the related statements of operations,
shareholders' equity (deficit), and cash flows for the year then ended and for
the period from June 19, 1985 (inception) through May 31, 2004 (not presented
herein); and in our report dated July 12, 2004, we expressed an unqualified
opinion on those financial statements. In our opinion, the information set forth
in the accompanying balance sheet as of May 31, 2004 and in the accompanying
statements of operations, cash flows and shareholders' equity (deficit) is
fairly stated, in all material respects, in relation to the statements from
which it has been derived.
As discussed in note 4 to the financial statements, the Company adopted
Statement of Financial Accounting Standards No. 143, "Accounting for Asset
Retirement Obligations," as of June 1, 2003.
/s/ KPMG LLP
Chicago, Illinois
April 8, 2005
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Balance Sheets
February 28, 2005 and May 31, 2004
FEBRUARY 28, MAY 31,
2005 2004
------------------ ------------
(unaudited)
ASSETS
Current assets:
Cash $ 14,290,996 39,042,884
Marketable securities 87,996,613 3,443,825
Prepaid expenses 353,396 614,664
Other current assets 80,471 1,082
------------------ ------------
Total current assets 102,721,476 43,102,455
Property, plant, and equipment 14,723,138 14,521,555
Accumulated depreciation (13,992,758) (13,515,061)
------------------ ------------
Net property, plant and equipment 730,380 1,006,494
------------------ ------------
Other assets 69,631 70,389
------------------ ------------
$ 103,521,487 44,179,338
================== ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 1,448,859 1,837,651
Accrued expenses 51,891 117,007
Accrued compensation and benefits 365,860 418,813
------------------ ------------
Total current liabilities 1,866,610 2,373,471
Other liabilities 251,655 252,756
------------------ ------------
Total liabilities 2,118,265 2,626,227
------------------ ------------
Shareholders' equity:
Preferred stock, $.01 par value. Authorized 5,000,000 shares;
none issued and outstanding -- --
Common stock, $.01 par value. Authorized 30,000,000 shares;
issued and outstanding 26,745,239 at February 28, 2005
and 21,398,439 at May 31, 2004 267,452 213,984
Additional paid-in capital 240,959,244 166,534,302
Deficit accumulated during the development stage (139,685,801) (125,039,555)
Deferred compensation (137,673) (155,620)
------------------ ------------
Total shareholders' equity 101,403,222 41,553,111
------------------ ------------
$ 103,521,487 44,179,338
================== ============
See accompanying notes to financial statements and accountants' review report.
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Statements of Operations
Three and nine months ended February 28, 2005 and February 29, 2004 and for the
period from June 19, 1985 (inception) through February 28, 2005
CUMULATIVE
THREE MONTHS ENDED NINE MONTHS ENDED FROM
FEBRUARY 28, FEBRUARY 29, FEBRUARY 28, FEBRUARY 29, JUNE 19, 1985
------------ ----------- ----------- ------------ (INCEPTION) THROUGH
2005 2004 2005 2004 FEBRUARY 28, 2005
------------ ----------- ----------- ------------ ------------------
(UNAUDITED) (UNAUDITED) (UNAUDITED) (UNAUDITED) (UNAUDITED)
------------ ----------- ----------- ------------ ------------------
Revenues - license income $ -- -- -- -- 3,000,000
------------ ---------- ----------- ----------- ------------
Costs and expenses:
Research and development 3,817,764 2,630,387 12,033,650 7,387,751 119,049,705
General and administrative 1,310,923 882,914 3,169,711 2,587,086 47,623,694
------------ ---------- ----------- ----------- ------------
5,128,687 3,513,301 15,203,361 9,974,837 166,673,399
------------ ---------- ----------- ----------- ------------
Other income and expense:
Interest income 281,109 28,880 557,115 77,352 24,145,753
Interest expense -- -- -- -- 83,234
------------ ---------- ----------- ----------- ------------
281,109 28,880 557,115 77,352 24,062,519
------------ ---------- ----------- ----------- ------------
Cumulative effect of change in
accounting principle -- -- -- 74,921 74,921
------------ ---------- ----------- ----------- ------------
Net loss $ (4,847,578) (3,484,421) (14,646,246) (9,972,406) (139,685,801)
============ ========== =========== =========== ============
Net loss per share - basic and diluted $ (0.21) (0.20) (0.67) (0.62) (13.07)
============ ========== =========== =========== ============
Shares used in calculation of
per share data - basic and diluted 22,658,213 17,092,979 21,829,722 16,069,729 10,684,774
============ ========== =========== =========== ============
See accompanying notes to financial statements and accountants' review report.
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Statements of Shareholders' Equity (Deficit)
Nine months ended February 28, 2005 and for the period
from June 19, 1985 (inception) through February 28, 2005
PREFERRED STOCK COMMON STOCK
-------------------- -----------------------
NUMBER AGGREGATE NUMBER AGGREGATE
OF SHARES AMOUNT OF SHARES AMOUNT
--------- --------- ----------- -----------
Issuance of common stock on August 27, 1985 -- $ -- 3,500,000 $ 35,000
Issuance of Series A convertible preferred stock at $4.00
per share on August 27, 1985 (net of costs of issuance
of $79,150) -- -- -- --
Net loss -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1986 -- -- 3,500,000 35,000
Net loss -- -- -- --
Deferred compensation relating to grant of stock options -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1987 -- -- 3,500,000 35,000
Issuance of Series B convertible preferred stock at
$35.68 per share on August 14, 1987 (net of costs of
issuance of $75,450) -- -- -- --
Net loss -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1988 -- -- 3,500,000 35,000
Issuance of common stock at $24.21 per share on June 7,
1988 (net of costs of issuance of $246,000) -- -- 413,020 4,130
Conversion of Series A convertible preferred stock to
common stock on June 7, 1988 -- -- 1,250,000 12,500
Conversion of Series B convertible preferred stock to
common stock on June 7, 1988 -- -- 1,003,165 10,032
Exercise of stock options at $2.00 per share -- -- 47,115 471
Issuance of common stock at $28.49 per share on March 6,
1989 (net of costs of issuance of $21,395) -- -- 175,525 1,755
Issuance of common stock at $28.49 per share on March 30,
1989 (net of costs of issuance of $10,697) -- -- 87,760 878
Sale of options at $28.29 per share to purchase common
stock at $.20 per share on March 30, 1989 (net of costs of
issuance of $4,162) -- -- -- --
Net loss -- -- -- --
Deferred compensation relating to grant of stock options -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1989 -- -- 6,476,585 64,766
Net loss -- -- -- --
Deferred compensation relating to grant of stock options -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1990 -- -- 6,476,585 64,766
Net loss -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1991 -- -- 6,476,585 64,766
Exercise of stock warrants at $5.60 per share -- -- 90,000 900
Net loss -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1992 -- -- 6,566,585 65,666
Exercise of stock warrants at $7.14 per share -- -- 15,000 150
Issuance of common stock at $15.19 per share on April 19,
1993 (net of costs of issuance of $20,724) -- -- 374,370 3,744
Net loss -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1993 -- -- 6,955,955 69,560
Net loss -- -- -- --
Issuance of common stock at $6.50 per share on May 26,
1994 (net of costs of issuance of $2,061,149) -- -- 2,500,000 25,000
Cancellation of stock options -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1994 -- -- 9,455,955 94,560
Net loss -- -- -- --
Issuance of common stock at $6.50 per share on June 20,
1994 (net of issuance costs of $172,500) -- -- 375,000 3,750
Exercise of stock options at $7.14 per share -- -- 10,000 100
Exercise of stock options at $2.00 per share -- -- 187,570 1,875
Cancellation of stock options -- -- -- --
Amortization of deferred compensation -- -- -- --
--- -------- ---------- -----------
Balance at May 31, 1995 -- $ -- 10,028,525 $ 100,285
See accompanying notes to financial statements and accountants' review report.
SERIES A CONVERTIBLE SERIES B CONVERTIBLE DEFICIT TOTAL
PREFERRED STOCK PREFERRED STOCK ACCUMULATED SHARE-
---------------------- ---------------------- ADDITIONAL DURING THE DEFERRED HOLDERS'
NUMBER AGGREGATE NUMBER AGGREGATE PAID-IN DEVELOPMENT COMPEN- EQUITY
OF SHARES AMOUNT OF SHARES AMOUNT CAPITAL STAGE SATION (DEFICIT)
--------- ---------- --------- ---------- ------------- ------------- ------------- -------------
-- $ -- -- $ -- $ (28,000) $ -- $ -- $ 7,000
250,000 250,000 -- -- 670,850 -- -- 920,850
-- -- -- -- -- (607,688) -- (607,688)
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
250,000 250,000 -- -- 642,850 (607,688) -- 320,162
-- -- -- -- -- (2,429,953) -- (2,429,953)
-- -- -- -- 2,340,000 -- (2,340,000) --
-- -- -- -- -- -- 720,000 720,000
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
250,000 250,000 -- -- 2,982,850 (3,037,641) (1,620,000) (1,389,791)
-- -- 200,633 200,633 6,882,502 -- -- 7,083,135
-- -- -- -- -- (3,057,254) -- (3,057,254)
-- -- -- -- -- -- 566,136 566,136
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
250,000 250,000 200,633 200,633 9,865,352 (6,094,895) (1,053,864) 3,202,226
-- -- -- -- 9,749,870 -- -- 9,754,000
(250,000) (250,000) -- -- 237,500 -- -- --
-- -- (200,633) (200,633) 190,601 -- -- --
-- -- -- -- 93,759 -- -- 94,230
-- -- -- -- 4,976,855 -- -- 4,978,610
-- -- -- -- 2,488,356 -- -- 2,489,234
-- -- -- -- 7,443,118 -- -- 7,443,118
-- -- -- -- -- (791,206) -- (791,206)
-- -- -- -- 683,040 -- (683,040) --
-- -- -- -- -- -- 800,729 800,729
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
-- -- -- -- 35,728,451 (6,886,101) (936,175) 27,970,941
-- -- -- -- -- (3,490,394) -- (3,490,394)
-- -- -- -- 699,163 -- (699,163) --
-- -- -- -- -- -- 546,278 546,278
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
-- -- -- -- 36,427,614 (10,376,495) (1,089,060) 25,026,825
-- -- -- -- -- (5,579,872) -- (5,579,872)
-- -- -- -- -- -- 435,296 435,296
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
-- -- -- -- 36,427,614 (15,956,367) (653,764) 19,882,249
-- -- -- -- 503,100 -- -- 504,000
-- -- -- -- -- (7,006,495) -- (7,006,495)
-- -- -- -- -- -- 254,025 254,025
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
-- -- -- -- 36,930,714 (22,962,862) (399,739) 13,633,779
-- -- -- -- 106,890 -- -- 107,040
-- -- -- -- 5,663,710 -- -- 5,667,454
-- -- -- -- -- (8,066,609) -- (8,066,609)
-- -- -- -- -- -- 254,025 254,025
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
-- -- -- -- 42,701,314 (31,029,471) (145,714) 11,595,689
-- -- -- -- -- (7,363,810) -- (7,363,810)
-- -- -- -- 14,163,851 -- -- 14,188,851
-- -- -- -- (85,400) -- 85,400 --
-- -- -- -- -- -- 267 267
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
-- -- -- -- 56,779,765 (38,393,281) (60,047) 18,420,997
-- -- -- -- -- (7,439,013) -- (7,439,013)
-- -- -- -- 2,261,250 -- -- 2,265,000
-- -- -- -- 71,300 -- -- 71,400
-- -- -- -- 373,264 -- -- 375,139
-- -- -- -- (106,750) -- 106,750 --
-- -- -- -- -- -- (67,892 (67,892)
-------- ---------- --------- ---------- ------------- ------------- ------------- -------------
-- $ -- -- $ -- $ 59,378,829 $ (45,832,294) $ (21,189) $ 13,625,631
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Statements of Shareholders' Equity (Deficit)
Nine months ended February 28, 2005 and for the period
from June 19, 1985 (inception) through February 28, 2005
PREFERRED STOCK COMMON STOCK
--------------------- -------------------------
NUMBER AGGREGATE NUMBER AGGREGATE
OF SHARES AMOUNT OF SHARES AMOUNT
--------- --------- ---------- ------------
Net loss -- $ -- -- $ --
Issuance of common stock at $17.75 per share on August 9, 1995
(net of issuance costs of $3,565,125) -- -- 2,925,000 29,250
Issuance of common stock at $17.75 per share on September 11,
1995 (net of issuance costs of $423,238) -- -- 438,750 4,388
Exercise of stock options at $2.00 per share -- -- 182,380 1,824
Exercise of stock options at $6.38 per share -- -- 1,500 15
Exercise of stock options at $7.14 per share -- -- 10,000 100
Cancellation of stock options -- -- -- --
Amortization of deferred compensation -- -- -- --
--- --------- ---------- ------------
Balance at May 31, 1996 -- -- 13,586,155 135,862
Net loss -- -- -- --
Exercise of stock options at $0.20 per share -- -- 263,285 2,633
Exercise of stock options at $2.00 per share -- -- 232,935 2,329
Exercise of stock options at $7.14 per share -- -- 10,000 100
Amortization of deferred compensation -- -- -- --
--- --------- ---------- ------------
Balance at May 31, 1997 -- -- 14,092,375 140,924
Net loss -- -- -- --
Exercise of stock options at $7.14 per share -- -- 5,000 50
Amortization of deferred compensation -- -- -- --
--- --------- ---------- ------------
Balance at May 31, 1998 -- -- 14,097,375 140,974
Net loss -- -- -- --
Non-cash compensation -- -- -- --
Exercise of stock options at $7.14 per share -- -- 17,500 175
Exercise of stock warrants at $8.00 per share -- -- 125,000 1,250
--- --------- ---------- ------------
Balance at May 31, 1999 -- -- 14,239,875 142,399
Net loss -- -- -- --
Non-cash compensation -- -- -- --
Exercise of stock options at $13.38 per share -- -- 2,500 25
--- --------- ---------- ------------
Balance at May 31, 2000 -- -- 14,242,375 142,424
Net loss -- -- -- --
Non-cash compensation -- -- -- --
Exercise of stock options at $6.38 per share -- -- 6,000 60
Exercise of stock options at $10.81 per share -- -- 17,500 175
--- --------- ---------- ------------
Balance at May 31, 2001 -- -- 14,265,875 142,659
Net loss -- -- -- --
--- --------- ---------- ------------
Balance at May 31, 2002 -- -- 14,265,875 142,659
Net loss -- -- -- --
--- --------- ---------- ------------
Balance at May 31, 2003 -- -- 14,265,875 142,659
Issuance of common stock at $5.60 per share on July 28, 2003
(net of costs of issuance of $909,229) -- -- 1,892,857 18,928
Issuance of common stock to directors at $6.08 per share on
October 30, 2003 -- -- 12,335 123
Deferred compensation related to stock grants -- -- 25,500 255
Amortization of deferred compensation -- -- -- --
Issuance of common stock at $5.80 per share on January 29, 2004
(net of costs of issuance of $1,126,104) -- -- 2,585,965 25,860
Issuance of common stock at $5.80 per share on February 18, 2004
(net of costs of issuance of $116,423) -- -- 237,008 2,370
Issuance of common stock at $5.80 per share on April 15, 2004
(net of costs of issuance of $192,242) -- -- 409,483 4,095
Issuance of common stock at $12.00 per share on May 18, 2004
(net of costs of issuance of $1,716,831.36) -- -- 1,954,416 19,544
Exercise of stock options at $6.38 per share -- -- 15,000 150
Net loss -- -- -- --
--- --------- ---------- ------------
Balance at May 31, 2004 21,398,439 213,984
Exercise of stock options at $6.38 per share -- -- 6,000 60
Deferred compensation related to stock grants -- -- 5,500 55
Amortization of deferred compensation -- -- -- --
Exercise of stock options at $7.83 per share -- -- 2,500 25
Exercise of stock options at $13.38 per share -- -- 20,000 200
Exercise of stock options at $10.88 per share -- -- 18,000 180
Exercise of stock options at $10.81 per share -- -- 95,000 950
Exercise of stock options at $7.43 per share -- -- 12,500 125
Exercise of stock options at $7.13 per share -- -- 875 9
Exercise of stock options at $10.66 per share -- -- 2,500 25
Exercise of stock options at $14.17 per share -- -- 1,500 15
Exercise of stock options at $5.15 per share -- -- 1,500 15
Issuance of common stock to directors at $12.66 per share on
September 21, 2004 -- -- 5,925 59
Issuance of common stock at $15.00 per share on February 9,
2005 (net of costs of issuance of $4,995,689) -- -- 5,175,000 51,750
Net loss -- -- -- --
--- --------- ---------- ------------
Balance at February 28, 2005 (unaudited) $ 26,745,239 $ 267,452
See accompanying notes to financial statements and accountants' review report.
SERIES A CONVERTIBLE SERIES B CONVERTIBLE DEFICIT
PREFERRED STOCK PREFERRED STOCK ACCUMULATED TOTAL
-------------------- -------------------- ADDITIONAL DURING THE SHAREHOLDERS'
NUMBER AGGREGATE NUMBER AGGREGATE PAID-IN DEVELOPMENT DEFERRED EQUITY
OF SHARES AMOUNT OF SHARES AMOUNT CAPITAL STAGE COMPENSATION (DEFICIT)
--------- --------- --------- --------- ------------- ------------------ --------------- -----------------
-- $ -- -- $ -- $ -- $ (4,778,875) $ -- $ (4,778,875)
-- -- -- -- 48,324,374 -- -- 48,353,624
-- -- -- -- 7,360,187 -- -- 7,364,575
-- -- -- -- 362,937 -- -- 364,761
-- -- -- -- 9,555 -- -- 9,570
-- -- -- -- 71,300 -- -- 71,400
-- -- -- -- (80,062) -- 80,062 --
-- -- -- -- -- -- (62,726) (62,726)
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 115,427,120 (50,611,169) (3,853) 64,947,960
-- -- -- -- -- (4,245,693) -- (4,245,693)
-- -- -- -- 50,025 -- -- 52,658
-- -- -- -- 463,540 -- -- 465,869
-- -- -- -- 71,300 -- -- 71,400
-- -- -- -- -- -- 2,569 2,569
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 116,011,985 (54,856,862) (1,284) 61,294,763
-- -- -- -- -- (5,883,378) -- (5,883,378)
-- -- -- -- 35,650 -- -- 35,700
-- -- -- -- -- -- 1,284 1,284
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 116,047,635 (60,740,240) -- 55,448,369
-- -- -- -- -- (7,416,333) -- (7,416,333)
-- -- -- -- 14,354 -- 14,354
-- -- -- -- 124,775 -- -- 124,950
-- -- -- -- 998,750 -- -- 1,000,000
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 117,185,514 (68,156,573) -- 49,171,340
-- -- -- -- -- (9,167,070) -- (9,167,070)
-- -- -- -- 57,112 -- -- 57,112
-- -- -- -- 33,425 -- -- 33,450
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 117,276,051 (77,323,643) -- 40,094,832
-- -- -- -- -- (10,174,609) -- (10,174,609)
-- -- -- -- -- -- -- --
-- -- -- -- 38,220 -- -- 38,280
-- -- -- -- 189,000 -- -- 189,175
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 117,503,271 (87,498,252) -- 30,147,678
-- -- -- -- -- (10,717,360) -- (10,717,360)
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 117,503,271 (98,215,612) -- 19,430,318
-- -- -- -- -- (12,250,145) -- (12,250,145)
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 117,503,271 (110,465,757) -- 7,180,173
-- -- -- -- 9,671,843 -- -- 9,690,771
-- -- -- -- 74,877 -- -- 75,000
-- -- -- -- 190,995 -- (191,250) --
-- -- -- -- -- -- 35,630 35,630
-- -- -- -- 13,846,633 -- -- 13,872,493
-- -- -- -- 1,255,853 -- -- 1,258,223
-- -- -- -- 2,178,664 -- -- 2,182,759
-- -- -- -- 21,716,616 -- -- 21,736,160
-- -- -- -- 95,550 -- -- 95,700
-- -- -- -- -- (14,573,798) -- (14,573,798)
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- -- -- -- 166,534,302 (125,039,555) (155,620) 41,553,111
-- -- -- -- 38,220 -- -- 38,280
-- -- -- -- 71,055 -- (71,110) --
-- -- -- -- -- -- 89,057 89,057
-- -- -- -- 19,550 -- -- 19,575
-- -- -- -- 267,400 -- -- 267,600
-- -- -- -- 195,660 -- -- 195,840
-- -- -- -- 1,026,000 -- -- 1,026,950
-- -- -- -- 92,750 -- -- 92,875
-- -- -- -- 6,230 -- -- 6,239
-- -- -- -- 26,625 -- -- 26,650
-- -- -- -- 21,240 -- -- 21,255
-- -- -- -- 7,710 -- -- 7,725
-- -- -- -- 74,941 -- -- 75,000
-- -- -- -- 72,577,561 -- -- 72,629,311
-- -- -- -- -- (14,646,246) -- (14,646,246)
--- --------- --- --------- ------------- ------------------ --------------- -----------------
-- $ -- -- $ -- $ 240,959,244 $ (139,685,801) $ (137,673) $ 101,403,222
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Statements of Cash Flows
Nine months ended February 28, 2005 and 2004
and for the period from June 19, 1985
(inception) through February 28, 2005
CUMULATIVE
FROM
NINE MONTHS ENDED FEBRUARY JUNE 19, 1985
----------------------------- (INCEPTION) THROUGH
28, 2005 29, 2004 FEBRUARY 28, 2005
-------------- ------------ -------------------
(UNAUDITED) (UNAUDITED) (UNAUDITED)
Cash flows from operating activities:
Net loss $ (14,646,246) (9,972,406) (139,685,801)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization 470,605 519,850 18,235,560
Non-cash compensation 164,055 86,767 3,827,408
Loss on sale of equipment -- -- 66,359
Changes in assets and liabilities: --
Prepaid expenses 261,268 425,691 (562,607)
Other current assets (79,389) (29,367) (1,976,722)
Other assets -- (14,907) 6,851
Accounts payable (388,792) (906,300) 1,448,859
Accrued expenses (65,116) (25,908) 51,891
Accrued compensation and benefits (52,954) (53,054) 365,860
Other liabilities (1,101) 94,120 251,655
-------------- ---------- ------------
Net cash used in operating activities (14,337,670) (9,875,514) (117,970,687)
-------------- ---------- ------------
Cash flows from investing activities:
Purchase of property, plant, equipment, and capitalized
engineering costs (201,582) (72,505) (18,963,885)
Proceeds from sale of land and equipment -- -- 1,863,023
Proceeds from matured marketable securities 11,225,000 2,000,000 422,762,352
Proceeds from sale of marketable securities -- -- 7,141,656
Purchase of marketable securities (95,769,935) (3,072,260) (517,834,342)
-------------- ---------- ------------
Net cash provided by (used in) investing activities (84,746,517) (1,144,765) (105,031,196)
-------------- ---------- ------------
Cash flows from financing activities:
Proceeds from issuance of common stock 79,327,988 26,973,243 235,974,307
Payment of common stock issuance costs (4,995,689) (2,151,756) (14,128,531)
Proceeds from issuance of preferred stock -- -- 6,644,953
Proceeds from sale of stock options to purchase common shares -- -- 7,443,118
Proceeds from issuance of notes payable -- -- 1,500,000
Repayment of notes payable -- -- (140,968)
-------------- ---------- ------------
Net cash provided by financing activities 74,332,299 24,821,487 237,292,879
-------------- ---------- ------------
Net (decrease) increase in cash (24,751,888) 13,801,208 14,290,996
Cash at beginning of period 39,042,884 4,897,962 --
-------------- ---------- ------------
Cash at end of period $ 14,290,996 18,699,170 14,290,996
============== ========== ============
See accompanying notes to financial statements and accountants' review report.
NORTHFIELD LABORATORIES INC.
(A COMPANY IN THE DEVELOPMENT CHANGE)
NOTES TO FINANCIAL STATEMENTS
FEBRUARY 28, 2005
(UNAUDITED)
(1) BASIS OF PRESENTATION
The interim financial statements presented are unaudited but, in the opinion of
management, have been prepared in conformity with accounting principles
generally accepted in the United States of America applied on a basis consistent
with those of the annual financial statements. Such interim financial statements
reflect all adjustments (consisting of normal recurring accruals) necessary for
a fair presentation of the financial position and the results of operations for
the interim periods presented. The results of operations for the interim periods
presented are not necessarily indicative of the results to be expected for the
full fiscal years. The interim financial statements should be read in connection
with the audited financial statements for the year ended May 31, 2004.
(2) USE OF ESTIMATES
Our management has made a number of estimates and assumptions relating to the
reporting of assets and liabilities and the disclosure of contingent assets and
liabilities to prepare these financial statements in conformity with accounting
principles generally accepted in the United States of America. Actual results
could differ from those estimates.
(3) COMPUTATION OF NET LOSS PER SHARE
Basic earnings per share is based on the weighted average number of shares
outstanding and excludes the dilutive effect of unexercised common stock
equivalents. Diluted earnings per share is based on the weighted average number
of shares outstanding and includes the dilutive effect of unexercised common
stock equivalents. Because we reported net losses for all periods presented,
basic and diluted per share amounts are the same. As of February 28, 2005, we
have 1,385,125 options and 212,392 warrants that were excluded from the net loss
per share calculation because their inclusion would have been antidilutive.
(4) ASSET RETIREMENT OBLIGATIONS
We adopted Statement of Financial Accounting Standards, SFAS No. 143 -
"Accounting for Asset Retirement Obligations" as of June 1, 2003. The cumulative
effect of the change in accounting principle upon implementation was to
recognize a net asset of $17,800, an increase in liabilities of $92,721 and an
increase in net loss of $74,921, or $0.01 per share.
The obligation relates to the restoration of a leased manufacturing facility to
its original condition. A liability of $100,000 had been recorded in a prior
period.
Our asset retirement obligations are included in other liabilities. The balances
and changes thereto are summarized below:
Quarter Ended February 28, 2005
-------------------------------
(unaudited)
Obligation at May 31, 2004 $ 210,066
Accretion 14,179
---------
Obligation at February 28, 2005 $ 224,245
=========
If the change in accounting had been applied retroactively, our pro forma net
loss for the nine-months ended February 29, 2004 would have been $9,897,485,
with no change in loss per share.
(5) STOCK OPTIONS
We account for our fixed plan stock options under the intrinsic value method of
accounting prescribed by Accounting Principles Board Opinion No. 25, "Accounting
for Stock Issued to Employees", and related interpretations in accounting for
options granted to directors, officers, and key employees under the plans. As
such, compensation expense is recorded on the date of grant and amortized over
the period of service only if the current market value of the underlying stock
exceeded the exercise price. No stock option based employee compensation cost is
reflected in net loss, as each option granted under these plans had an exercise
price equal to the market value of the underlying common stock on the date of
grant.
The following table illustrates the effect on net loss if we had applied the
fair value recognition provisions of Statement of Financial Accounting Standards
(SFAS) No. 123, "Accounting for Stock Based Compensation" to the measurement of
stock-based employee compensation, including a straight-line recognition of
compensation costs over the related vesting periods for fixed awards:
Three Months Ended Nine Months ended
February 28, February 29, February 28, February 29,
2005 2004 2005 2004
------------- ------------- ------------- ------------
(unaudited) (unaudited) (unaudited) (unaudited)
Net loss as reported $ (4,847,578) (3,484,421) (14,646,246) (9,972,406)
Add: Stock based compensation
expense included in statements
of operations................... 32,346 11,767 164,055 86,767
Deduct: Total stock based
compensation expense
determined under the fair
value method for all awards, (507,347) (156,098) (1,400,648) (590,712)
------------ ---------- ----------- -----------
(5,322,579) (3,628,752) (15,882,839) (10,476,351)
Basic and diluted loss per share:
As reported (0.21) (0.20) (0.67) (0.62)
Pro forma (0.23) (0.21) (0.73) (0.65)
============ ========== =========== ===========
(6) RECENTLY ISSUED ACCOUNTING STANDARD
In December 2004, Statement of Financial Accounting Standards (SFAS) No. 123
(Revised 2004), "Share-Based Payment: an amendment of FASB Statements No. 123
and 95", was issued. This Statement amends SFAS No. 123, "Accounting for
Stock-Based Compensation", and requires companies to recognize in the income
statement the grant-date fair value of stock options and other equity-based
compensation issued to employees. The Statement is effective for public
companies with interim or annual periods beginning after June 15, 2005. The
Company will adopt SFAS 123(R) for the three-month period ended November 30,
2005. The Company will assess the impact of the transition to this new
accounting standard during the upcoming months.
(7) MARKETABLE SECURITIES
In February, 2005, the Company completed an underwritten public offering of
5,175,000 shares of common stock. The offering resulted in gross proceeds of
$77.6 million. The Company on a short-term basis invested these proceeds in
U.S. Treasury Securities, obligations of U.S. government agencies and high grade
commercial paper.
The fair market value of the Company's marketable securities was $87,858,238 at
February 28, 2005, which included gross unrealized holding losses of $138,375.
The fair market value of the Company's marketable securities was $3,441,669 at
May 31, 2004, which included gross unrealized holding losses of $2,156. All of
these marketable securities are scheduled to mature in less than one year.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
RECENT DEVELOPMENTS
We are currently enrolling patients in a pivotal Phase III trial in which
our PolyHeme(R) human blood substitute product is being used for the first time
in civilian, urban trauma settings to treat severely injured patients in
hemorrhagic shock before they reach the hospital. Under this protocol, treatment
with PolyHeme begins at the scene of the injury or in the ambulance and
continues during transport and the initial 12-hour post-injury period in the
hospital. Since blood is not presently carried in ambulances, the use of
PolyHeme in this setting has the potential to improve survival and address a
critical, unmet medical need.
As of April 8, 2005, 17 clinical sites in the United States were enrolling
patients in our pivotal Phase III trial and five other sites had received final
Institutional Review Board, or IRB, approval and were preparing to begin patient
enrollment. Multiple additional sites were engaged in the pre-trial public
disclosure and community consultation process. Each of the sites participating
in the trial is designated as a Level I trauma center, indicating its capacity
to treat the most severely injured trauma patients. We anticipate that a total
of 25 or more clinical sites across the United States will eventually
participate in the trial. The trial has an expected enrollment of 720 patients.
As part of our trial protocol, an Independent Data Monitoring Committee,
or IDMC, is responsible for periodically evaluating the safety data from the
trial and making recommendations relating to the continuation or modification of
the trial protocol to minimize any identified risks to patients. The protocol
includes four planned evaluations by the IDMC that occur after 60, 120, 250 and
500 patients have been enrolled and monitored for a 30-day follow up period. The
IDMC focuses its reviews on mortality and serious adverse events and evaluates
all safety data as the trial continues. We receive a recommendation from the
IDMC after each review, but we will not have access to the trial data reviewed
by the IDMC until the trial is completed.
We recently announced the IDMC recommendation that our trial continue
without modification based on the committee's initial review of blinded data on
mortality and serious adverse events from the first 250 patients enrolled in the
trial. The IDMC made similar recommendations in June and October 2004 following
its first two evaluations of safety data from our trial.
The length of time for completion of the IDMC review after each enrollment
target is reached is expected to become longer as the number of enrolled
patients increases. Enrollment in the trial continues during the period of
30-day follow-up, data preparation and analysis and meetings of the IDMC, so the
disclosure of the IDMC recommendation does not correspond to the current status
of patient enrollment. We anticipate that the IDMC will complete its final
interim review of safety data on the first 500 patients enrolled in our trial
and make a recommendation to us in the fourth calendar quarter of 2005.
Our current goal is to complete the patient enrollment phase of our trial
by the end of calendar 2005. Our ability to achieve this goal will depend, in
part, on the number of clinical sites participating in our trial and the ability
of these sites to enroll patients at the projected rates.
The progress of our pivotal Phase III trial and the timing and outcome of
the Food and Drug Administration, or FDA, review process are subject to
significant risks and uncertainties,
many of which are outside of our control. We urge you to review the "Risk
Factors" section in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission for a discussion of certain of these risks
and uncertainties.
In February 2005, we announced the completion of an underwritten public
offering of 5,175,000 shares of our common stock. The offering resulted in gross
proceeds of approximately $77.6 million. We intend to use the proceeds of this
offering to fund our post-enrollment activities in our clinical trial, to
prepare and submit a Biologics License Application to FDA, to prepare for the
commercial launch of PolyHeme, to fund ongoing business operations and for other
general corporate purposes.
Since Northfield's incorporation in 1985, we have devoted substantially
all of our efforts and resources to the research, development and clinical
testing of PolyHeme. We have incurred operating losses during each year of our
operations since inception and expect to incur substantial additional operating
losses for the next several years. From Northfield's inception through February
28, 2005, we have incurred operating losses totaling $139,686,000.
We will be required to complete our pivotal Phase III trial and obtain
regulatory approval from the FDA before PolyHeme can be sold commercially. The
FDA regulatory process is subject to significant risks and uncertainties. We
therefore cannot at this time reasonably estimate the timing of any future
revenues from the commercial sale of PolyHeme. The costs incurred by Northfield
to date and during each period presented below in connection with our
development of PolyHeme are described in the Statements of Operations in our
financial statements.
Our success will depend on several factors, including our ability to
obtain FDA regulatory approval of PolyHeme and our manufacturing facilities,
obtain sufficient quantities of blood to manufacture PolyHeme in commercial
quantities, manufacture and distribute PolyHeme in a cost-effective manner,
enforce our patent positions and raise sufficient capital to fund these
activities. We have experienced significant delays in the development and
clinical testing of PolyHeme. We cannot ensure that we will be able to achieve
these goals or that we will be able to realize product revenues or profitability
on a sustained basis or at all.
RESULTS OF OPERATIONS
We reported no revenues for either of the three and nine-month periods
ended February 28, 2005 or February 29, 2004. From Northfield's inception
through February 28, 2005, we have reported total revenues of $3,000,000, all of
which were derived from licensing fees.
OPERATING EXPENSES
Operating expenses for our third fiscal quarter ended February 28, 2005
totaled $5,129,000, an increase of $1,616,000 from the $3,513,000 reported in
the third quarter of fiscal 2004. Measured on a percentage basis, fiscal 2005
operating expenses exceeded fiscal 2004 expenses by 46.0%. As expected,
significant increases in operating expenses were incurred to conduct, expand,
report and support our pivotal Phase III trial.
Research and development expense during the third quarter of fiscal 2005
totaled $3,818,000, an increase of $1,188,000, or 45.2%, from the $2,630,000
reported in the third quarter of fiscal 2004. Our pivotal Phase III trial is
enrolling patients and we continue to actively pursue additional clinical sites
to participate in the trial. We anticipate that these expenses will
continue to grow consistent with the rate of patient enrollment and site
initiation. Also included in the third quarter research and development expenses
was an increased use of science and regulatory consultants to prepare for the
reporting of data from our trial to FDA.
General and administrative expenses in the third quarter of fiscal 2005
totaled $1,311,000, which is an increase of $428,000, or 48.5%, from the
$883,000 of general and administrative expenses reported in the third quarter of
fiscal 2004. The increased expenses in the third quarter of fiscal 2005 compared
to the third quarter of fiscal year 2004 was due to increased compensation
expense, increased costs for employee benefits, increased taxes resulting from
our recently completed public offering and increased board compensation. We
anticipate only modest general and administrative expense increases in the
fourth quarter of fiscal 2005 compared to the fourth quarter of fiscal 2004. No
new general and administrative programs are currently planned, as successfully
completing our pivotal Phase III trial remains our primary focus.
For the nine-month period ended February 28, 2005, operating expenses of
$15,203,000 exceeded the operating expenses of $9,975,000 incurred in the
nine-month period ended February 29, 2004. The dollar increase was $5,228,000
and the percentage increase equaled 52.4%. The increases were primarily
attributed to the planning, preparation, execution, analysis and reporting of
our pivotal Phase III trial.
Research and development expenses for the nine-month period ended February
28, 2005 totaled $12,034,000, which represents a $4,646,000, or 62.9%, increase
from the comparable expenses incurred in the nine-month period ended February
29, 2004. During the current fiscal year, increased expense totaling $3,746,000
was reported for clinical site activities and related monitoring, analysis and
reporting. Additional expenses were also recorded to manufacture increased
quantities of PolyHeme for use in our trial. The cost of additional personnel
and higher benefit costs also added to the current year expenses.
General and administrative expenses for the nine-month period ended
February 28, 2005 totaled $3,170,000, which is an increase of $583,000, or
22.5%, from the $2,587,000 of general and administrative expenses reported for
the nine-month period ended February 29, 2004. The increased expenses this
fiscal year are due to compensation and benefits, professional services,
additional taxes payable based on our increased market capitalization and
expenses related to preparing for commercialization of PolyHeme.
INTEREST INCOME
Interest income for the three-month period ended February 28, 2005 totaled
$281,000, an increase of $252,000 from the $29,000 in interest income reported
in the three-month period ended February 29, 2004.
The increase in our interest income was primarily due to our improved cash
position resulting from our successful equity financing transactions during the
prior 12 months. Our reported cash balance of $21.7 million at the end of the
third quarter of fiscal 2004 compares with a cash and marketable securities
balance of $102.3 million at the end of our most recent fiscal quarter.
Combining increased cash availability and increasing short-term interest rates
has allowed us to report significantly higher interest income.
Interest income for the nine-month period ended February 28, 2005 totaled
$557,000, an increase of $480,000 from the $77,000 in interest income reported
in the nine-month period ended February 29, 2004. The increase in cash balances
and increases in available short-term
interest rates caused interest income to increase. We continue to invest our
funds only in high grade, short-term instruments.
NET LOSS
Our net loss for the three-month period ended February 28, 2005 totaled
$4,848,000, or $0.21 per share, compared to a net loss of $3,484,000, or $0.20
per share, for the three-month period ended February 29, 2004. In dollar terms,
the loss increased by 39.2%, primarily as a result of the increased expenses
relating to our pivotal Phase III trial. On a per share basis, however, the
additional 5,830,000 shares used in the calculation of per share data in the
current fiscal quarter mitigated the loss per share increase to 5.0%.
On a fiscal year to date basis, we reported a loss of $14,646,000, or
$0.67 per share, compared to a prior year nine-month loss of $9,972,000, or
$0.62 per share. The increased net loss of $4,674,000, or 46.9%, was primarily
the result of increased expenses relating to our pivotal Phase III trial during
the first nine-months of the current fiscal year. The per share loss was limited
by the dilutional effect of the additional 5,847,000 shares used in the
calculation of per share data in the current fiscal year nine-month data.
LIQUIDITY AND CAPITAL RESOURCES
From Northfield's inception through February 28, 2005, we have used cash
in operating activities and for the purchase of property, plant, equipment and
engineering services in the amount of $136,935,000. For the nine-months ended
February 28, 2005 and February 29, 2004, these cash expenditures totaled
$14,540,000 and $9,948,000, respectively. The current fiscal year nine-month
increase in cash utilization is due primarily to expenses related to our pivotal
Phase III trial.
We have financed our research and development and other activities to date
through the public and private sale of equity securities and, to a more limited
extent, through the license of product rights. As of February 28, 2005, we had
cash and marketable securities totaling $102,288,000. As previously reported, we
have also been successful in securing a $1.4 million federal appropriation as
part of the 2005 Defense Appropriation Bill. As of February 28, 2005, we have
not yet received these funds.
We are currently utilizing our cash resources at a rate of approximately
$20 million per year. We expect, however, that the rate at which we utilize our
cash resources will increase in the coming years as we seek to complete the FDA
approval process and begin planning for the commercial launch of PolyHeme.
We anticipate that our expenditures for site monitoring and patient
enrollment in connection with our current Phase III clinical trial will be
completed in calendar 2006, while substantial additional costs will be incurred
during calendar 2006 to complete and file a Biologics License Application for
PolyHeme with FDA. We also expect to incur additional expenses as we build
manufacturing, sales, marketing and distribution capabilities in support of the
commercialization of PolyHeme.
Based on our current estimates, we believe our existing capital resources
will be sufficient to permit us to conduct our operations, including the planned
expansion of our manufacturing, sales, marketing and distribution capabilities,
for the next two to three years.
Thereafter, we may issue additional equity or debt securities or enter
into collaborative arrangements with strategic partners, which could provide us
with additional funding or absorb expenses we would otherwise be required to
pay. We are also pursuing potential sources of additional government funding.
Any one or a combination of these sources may be utilized to raise additional
capital. We believe our ability to raise additional capital or enter into a
collaborative arrangement with a strategic partner will depend primarily on the
results of our clinical trial, as well as general conditions in the business and
financial markets.
Our capital requirements may vary materially from those now anticipated
because of the timing and results of our clinical testing of PolyHeme, the
establishment of relationships with strategic partners, changes in the scale,
timing or cost of our planned commercial manufacturing facility, competitive and
technological advances, the FDA regulatory process, changes in our marketing and
distribution strategy and other factors.
CRITICAL ACCOUNTING POLICIES
The preparation of financial statements requires management to make
estimates and assumptions that affect amounts reported therein. We believe the
following critical accounting policy reflects our more significant judgments and
estimates used in the preparation of our financial statements.
NET DEFERRED TAX ASSETS VALUATION
We record our net deferred tax assets in the amount that we expect to
realize based on projected future taxable income. In assessing the
appropriateness of our valuation, assumptions and estimates are required, such
as our ability to generate future taxable income. In the event we were to
determine that it was more likely than not we would be able to realize our
deferred tax assets in the future in excess of their carrying value, an
adjustment to recognize the deferred tax assets would increase income in the
period such determination was made. As of February 28, 2005, we have recorded a
100% percent valuation allowance against our net deferred tax assets.
CONTRACTUAL OBLIGATIONS
The following table reflects a summary of our contractual cash obligations
as of February 28, 2005:
LESS THAN 4-5
Contractual Obligations TOTAL ONE YEAR 1-3 YEARS YEARS
------------------------------ ----------- ----------- ------------ -----------
Lease Obligations (1) ........ $ 3,705,263 $ 840,842 $ 1,679,147 $ 1,185,274
Other Obligations (2)......... 1,251,250 1,251,250 -- --
----------- ----------- ------------ -----------
Total Contractual Cash Oblig.. $ 4,956,513 $ 2,092,092 $ 1,679,147 $ 1,185,274
=========== =========== ============ ===========
----------
(1) The lease for our Evanston headquarters is cancelable with six months
notice combined with a termination payment equal to three months base rent
at any time after February 14, 2009. If the lease is cancelled as of
February 15, 2009 unamortized broker commissions of $17,470 would also be
due.
(2) Represents payments required to be made upon termination of employment
agreements with two of our executive officers. The employment contracts
renew automatically unless terminated. Figures shown represent
compensation payble upon the termination of the employment agreements for
reasons other than death, disability, cause or voluntary termination of
employment by the executive officer other than for good reason.
Additional payments may be required under the employment agreements in
connection with a termination of employment of the executive officer
following a change in control of Northfield.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We currently do not have any foreign currency exchange risk. We invest our
cash and cash equivalents in government securities, certificates of deposit and
money market funds. These investments are subject to interest rate risk.
However, due to the nature of our short-term investments, we believe that the
financial market risk exposure is not material. A one percentage point decrease
in the interest rate received on our cash and marketable securities of $102.3
million at February 28, 2005 would decrease interest income by $1,023,000 on an
annual basis.
ITEM 4. CONTROLS AND PROCEDURES.
Based on their evaluation as of the end of the period covered by this
report, our Chief Executive Officer and Senior Vice President and Chief
Financial Officer have concluded that Northfield's disclosure controls and
procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934, are effective to ensure that information required to be
disclosed by us in the reports that we file or submit under the Securities
Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission's rules and forms.
There were no changes in our internal control over financial reporting that
occurred during our most recent fiscal quarter that have materially affected, or
are reasonably likely to materially affect, our internal control over financial
reporting.
PART II. OTHER INFORMATION
Item 6. Exhibits
a) Exhibit 15 - Acknowledgment of Independent Registered
Public Accounting Firm Regarding Accountants'
Review Report
Exhibit 31.1 - Certification of Steven A. Gould, M.D.,
pursuant to Rule 13a-14(a) under the
Securities Exchange Act of 1934
Exhibit 31.2 - Certification of Jack J. Kogut, pursuant to
Rule 13a-14(a) under the Securities Exchange
Act of 1934
Exhibit 32.1 - Certification of Steven A. Gould, M.D.,
pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002
Exhibit 32.2 - Certification of Jack J. Kogut, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
b) None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the Company
in the capacities indicated on April 11, 2005.
SIGNATURE TITLE
/s/ Steven A. Gould, M.D. Chairman of the Board and Chief
------------------------- Executive Officer
Steven A. Gould, M.D.
/s/ Jack J. Kogut Sr. Vice President and Chief
------------------------- Financial Officer
Jack J. Kogut